🇺🇸 FDA
Patent

US 8546091

AKT phosphorylation at Ser473 as an indicator for taxane-based chemotherapy

granted A61PA61P35/00A61P35/04

Quick answer

US patent 8546091 (AKT phosphorylation at Ser473 as an indicator for taxane-based chemotherapy) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Sep 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Oct 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61P, A61P35/00, A61P35/04